Table 7
US FDA Orphan Drug Approvals 1999
(New Chemical Entities)
Version 1.2
July 10, 2000
Thiru Balasubramaniam

Brand Name
 Panretin
 Temodar
Ellence
Aromasin
Curosurf
INOmax
Targretin
Generic Name
alitretinoin
temozolomide
epirubicin
exemestane
poractant alfa
nitric oxide
bexarotene
Patent 
No
Yes
No
Yes
No
Yes
Yes
Indication(s)
Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
Treatment of adult patients with refractory anaplastic astrocytoma
Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Treatment of advanced breast cancer in postmenopausal women whose disease has progress following tamoxifen therapy.
Treatment (rescue) of Respiratory Distress Syndrome in premature infants.
Treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory
failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Treatment of cutaneous manifestations of cutaneouse T-cell lymphoma in patients who refractory to at least one prior systemic therapy.
Company
 Ligand 
Schering-Plough
Pharmacia & Upjohn
Pharmacia & Upjohn
Dey
INO
Ligand
Inventor
 
Edward Lunt et al.
 
Franco Buzzeti et al.
 
Warren Zapol et al.
Marcia Dawson et al.
Assignee
 
Cancer Research Campaign Technology Limited (London, GB2)
 
Farmitalia Carlo Erba S.r.l.
 
The General Hospital Corporation (Boston, M.A.)
SRI International, La Jolla Cancer Research Foundation
Class
1PV
1PV
1PV
1SV
1SV
1PV
1PV
Cost to consumer over completed course treatment
$2,400.31 

(For 60gm tube: 2 months of treatment- applied twice a day)

Panretin is a palliative; treatment duration depends on patient response)

 *Range (Min. and Max. recommended daily dose based on body surface area): 
$29,029 -
$72,319

For two years of treatment depending on body size.   First figure: 200mg/day-5 consecutive days per 28 day treatment cycle.  Second figure: 500mg/day-5 consecutive days per 28 day treatment cycle.

(Drugstore.com)

Range (recommended  starting dose: 100 to 120 mg/square meter) 
 

$6000-$7200 (Pharmacia wholesaler cost-cost to consumer is much greater)

Treatment for 6 cycles; each cycle is 21 days)

$1673.67 

For 9 months supply (25 mg/day)

Median duration of treatment in clinical trials:  8.9 months

(Drugstore.com)


 

1.5 mL: $440
3.0 mL: $762

The initial recommended dose is 2.5mL/kg.
The maximum recommended dose is 5.0mL/kg.


 

 

INOtherapy Service:  $125/hour

Minimum duration: 24 hours (first day $3,000)

The total charge of INOtherapy Service per
patient in any given consecutive 30-day period is capped at $12,000.

Source: INO


 
 
*Range (Min. and Max. recommended daily dose based on body surface area): $13,028-$32,571

For one year's supply. 
First figure: 300mg/day

Second figure: 750mg/day

 Government Rights
           in Patent
-
No
-
No
-
Yes
No
Patent Number
Not applicable
5,260,291
Not applicable
4,808,616
Not applicable
5,485,827
5,466,861
Filing of Key Patent Application
-
18-Oct-91
-
7-Jul-86
-
10-Feb-95
25-Nov-92
Patent Approval
-
9-Nov-93
-
28-Feb-89
-
23-Jan-96
14-Nov-95
NDA Filing
27-May-98
13-Aug-98
15-Dec-98
21-Dec-98
.
16-Jun-97
23-Jun-99
NDA Approval
2-Feb-99
11-Aug-99
15-Sep-99
21-Oct-99
18-Nov-99
23-Dec-99
29-Dec-99
Time between Patent Filing and NDA Approval
Not applicable
7.82 years
Not applicable
13.30 years
Not applicable
4.87 years
7.10 years
# of Clinical Trials in
NDA
2
1
2
3
2
2
2
# of Patients in each Clinical Trial
Study 1:  268 patients

Study 2:  270 patients 

Study: 162 patients
MA-5: 716 patients

GFEA:  565 patients

Missing Data
Study 1: 145 patients 

Study 2: 357 patients

NIROS Study: 235 neonates

CINRGI Study: 186 patients

Missing Data
 Total # of Patients in Clinical Trials
538 patients
162 patients
1281 patients
1058 patients
502 patients
421 patients
152 patients


CPT Home IP and Healthcare CPT page on South Africa James Love's Affidavit